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1. Introduction
  Lung cancer is one of the world’s most common cancer 
which is harmful to human health. The vast majority of lung 
cancer is non-small cell lung cancer (NSCLC)[1,2]. Although 
there have been great development of diagnosis and therapy, 
the prognosis of lung cancer is not very well and has a high 
mortality. Epidermal growth factor receptor tyrosine kinase 
inhibitor (EGFR-TKI) has been applied to the treatment of 
NSCLC and improved the survival rate of some patients. 
However, it has limitation in its scope for patients with 
EGFR-TKI resistance, so we need to explore new treatments 
for lung cancer. It is discovered in recent years that target 
of rapamycin (mTOR) signaling pathway activation is closely 
related to tumor resistance mechanisms. Everolimus as 
mTOR inhibitor has attracted more and more attention[3-5]. 
This study aimed to investigate the effect of mTOR inhibitor 
on the proliferation and apoptosis of EGFR-TKI resistance 
NSCLC and provide experimental data for clinical 
application.
2. Materials and methods
2.1. Tumor Cell Lines
  Human non-small cell lung cancer cell line A549 were 
purchased from cell bank of Shanghai Institutes for 
Biological Sciences, Chinese Academy of Sciences. 
2.2. Reagents and instruments
  RPMI 1640 medium was purchased from Sigma, 
tetramethylrhodamine tetrazolium salt (MTT), formazan were 
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purchased from Gibco, fetal bovine serum, trypsin digestion 
enzymes were purchased from Sigma. PTEN and 4EBP1 are 
rabbit anti-human polyclonal antibody, propidium chloride 
was purchased from Beijing Solarbio company, Everolimus 
was  a gift from Novartis; It was dissolved in DMSO at
10 毺mol/L,-20 曟, 5% CO2, 37 曟. Saturated humidity 
ordinary cell incubator which was purchased from Shanghai 
Huaxian Medical Nuclear Instrument Co., Ltd. PCR 
amplification was purchased from Bio-Rad company. Flow 
cytometry was purchased from Beckman Coulter Company. 
Electric oven thermostat blast DHG-9246A type purchased 
from Beijing Liuyi Instrument Factory, centrifuge was 
purchased from the Eppendorf company, German.
2.3. Cell growth inhibition assay
  Human non-small cell lung cancer cell line A549 was 
placed in 5% CO2, 37 曟. After cell attachment, culture 
medium was changed and culture was continued. RPMI1640 
medium containing 10% fetal calf serum was used to stop the 
digestion, and the original culture medium was discarded 
when the A549 cells adherent reached to 80%. It was washed 
2 times with PBS then was added with 0.25% trypsin solution, 
the passage was cultured according to a certain proportion. 
The experiment was carried out when cells were in the 
logarithmic growth phase. A549 cells suspension in the 
logarithmic growth phase was adjusted to 6×104 cells/mL, 
and was cultured with 200 毺L cell suspension per well in 
96-well plates to set up a normal cell control group and 5 
drug experimental group. 
  In control group MTT dissolve solution was added, while 
in drug groups different concentrations of everolimus
200 毺L was added (A: 0.1 nmol/L, B: 1 nmol/L, C: 10 nmol/L,
D: 100 nmol/L, E: 1 000 nmol/L).After culturing for 48 h, 
10 毺L 5 mg/ml MTT solution was added to each well, and 
reincubated for 4 h. The supernatant were abandoned after 
blue-purple formazan was formed. It was washed in PBS 
for 2 times and was added with 150 毺L DMSO solution to 
dissolve formazan. It was divided into two parts after 4 h. 
A: the absorbance (A) value was measured in automatic 
microplate reader detector at 570 nm wavelength to calculate 
the killing rate. The killing rate (%) = [1 - (A effect target cell 
well -A effect cell well) / A target cell well] × 100%.B: 0.3-
0.5 mL propidium chloride dyeing solution was added. After 
flow cytometry detection,the rate of apoptosis was calculated 
with. Each independent experiment was repeated three 
times.
2.4. RT-PCR detection
  A549 cells were collected by TRIzol (Invitrogen Company) 
extraction of total RNA in tissues. cDNA was synthesized 
according to instructions. The cDNA was used as a template 
for PCR amplification, and GADPH was used as an internal 
reference. PTEN reaction conditions: after 95 曟 5 min, 95 曟
30 s → 62 曟 30 s → 72 曟 30 s, amplified for 35 cycles; 
72 曟 7 min, size of the products: 232 bp. PTEN reaction 
conditions: after 95 曟 5 min, 95 曟 30 s → 62 曟 30 s → 
72 曟 30 s, amplified for 35 cycles; 72 曟 7 min, size of the 
products: 232 bp.4EBP1 reaction conditions: after 95 曟
5 min, 95 曟 30 s → 53 曟 30 s → 72 曟 30 s, amplified for 
35 cycles; 72 曟 7 min, size of the products: 167 bp. 1.5% 
agarose gel electrophoresis and EB staining were carried 
out. GADPH was used as an internal reference to calculate 
the relative content of gene PTEN and 4EBP1 mRNA. Results 
were expressed by percentage ratio of the central point 
density PTEN, 4EBP1 in GADPH bands.
2.5. Statistical analysis
  All data was analyzed with SPSS 17.0 software. Data were 
expressed as mean依SD values. Mean comparison were 
compared with t test. P<0.05 was regarded as statistical 
significance.
3. Results
3.1. Impact of everolimus on proliferation of A549 cells
  After treatment with different concentrations of everolimus, 
24 h inhibition rates of A549 cells were (7.8依2.3)%, (15.2依
2.5)%, (21.2依3.4)%, (42.1依4.8)%, (67.0依6.4)%, 48 h inhibition 
rates were (15.6依2.6)%, (29.8依2.9)%, (34.3依4.3)%, (56.8依6.5)%, 
(80.7依7.8)%. There were statistically significant difference 
in the inhibition rate between different drug concentrations 
and different action time (P<0.05).
3.2. Impact of everolimus on A549 apoptosis
  After treatment with different concentrations of everolimus, 
24 h apoptosis rate of A549 cells were (1.1依0.2)%, (1.7依
0.2)%, (2.2依0.2)%, (3.4依0.3)%, (5.6依0.3)%, 48 h apoptosis rates 
were (2.1依0.2)%, (3.4依0.3)%, (6.3依0.4)%, (10.7依0.5)%, (16.5依
0.7)%. There were statistically significant difference in the 
inhibition rate between different drug concentrations and 
different action time (P<0.05). 
3.3. Impact of everolimus on A549 cells PTEN, 4EBP1 
mRNA expression levels
  PTEN and 4EBP1 expression in the experimental group were 
Xu-Dong Xiang et al./Asian Pacific Journal of Tropical Medicine (2014)394-397396
significantly higher than control group, and the expression 
was increased with everolimus drug concentration (Table 1, 
Figure 1).
Table 1
PTEN, 4EBP1 mRNA expression levels in each group.
PTEN 4EBP1
Control group 0.159依0.171 0.089依0.034
Experimental group A 0.221依0.223* 0.113依0.044*
Experimental group B 0.334依0.242*△ 0.134依0.051
*
Experimental C 0.429依0.279*△○ 0.167依0.062*△
Experimental D 0.487依0.310*△○ 0.198依0.058*△○
Experimental E 0.525依0.329*△○◇ 0.211依0.059*△○
Note: * Compared with the control group, P <0.05, △ Compared with 
the experimental group A, P <0.05, ○compared with the experimental 
group  B, P <0.05, ◇ compared with experimental group C, P <0.05.
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Figure 1. PTEN, 4EBP1 mRNA expression levels in each group.
4. Discussion
  The specific mechanism of non-small cell lung cancer 
resistance for EGFR-TKI is very complex. Currently a 
viable solution is to blocking tumor cell proliferation signal 
transduction pathway. mTOR is a key regulator of cyclin 
synthesis, which has two signaling pathways, one is PI3K/
AKT/mTOR pathway, another is AKT/TSC1-TSC2/mTOR 
pathway. Both promote cell proliferation by accelerating 
the G1-S cell cycle conversion; several studies suggest 
that mTOR signaling pathway plays an important role in 
tumor formation. Everolimus as a new mTOR inhibitor, 
and the mechanism of anti-tumor action is still unclear. 
Studies suggest that everolimus combined with high-dose 
cyclophosphamide can inhibit angiogenesis. It provides 
a new treatment for EGFR-TKI resistance by everolimus 
blocking mTOR signaling pathway[6-10].
  In this study, A549 cell line is EGFR wild-type. Early 
studies suggest that EGFR-TKI is ineffective on wild-
type EGFR NSCLC using A549 cells meet the requirements 
of the study. In this study, the experiment was performed 
in vitro. After the EGFR-TKI primary resistant cell lines 
exposure to everolimus, the result showed that everolimus 
can significantly inhibit A549 cells, which shows time and 
dose-dependent and easy to induce apoptosis, the results 
is similar to relevant research. Research shows everolimus 
is a safe and effective inhibitor of tumor growth, but some 
studies suggest that everolimus did not affect cell cycle, 
but directly induce apoptosis. PTEN is considered to be an 
important tumor suppressor gene which is the first tumor 
suppressor gene with phosphatase activity currently. It is 
widely mutant in malignant tumors. It can induce p21, p27, 
p57 expression and restrict cell division by inhibiting the 
activation of AKT protein overexpression and inhibit tumor 
cell adhesion by blocking integrin signaling pathway, it 
can also reduce VEGF and other vascular inflammatory 
cytokines.
  4EBP1 is the endogenous cap-dependent translation 
inhibitor[11,12]. This study showed that PTEN, 4EBP1 
expressions increased with everolimus drug concentration 
increase. It’s mechanism is everolimus can block mTOR 
signaling pathway, prompt PTEN overactive and inhibit the 
pathway related genes upstream and downstream, inhibit 
chemokine receptor expression[13-16]. 4EBP1 is the negative 
regulator gene of mTOR signaling pathway downstream. 
Studies suggest that 4EBP1 can reverse elF-4E[17-20], 
induced inactivation of mTOR signaling pathway, resulting 
in the effect of depressing carcinoma[21,22]. Therefore, mTOR 
inhibitors have been applied in varying degrees of treatment 
for various malignancies in recent years,which has its 
unique advantages as a multi-targeted anticancer drugs. 
  mTOR inhibitors can inhibit proliferation and promote 
apoptosis for EGFR-TKI resistance non-small cell lung 
cancer cells, but the safety and clinical efficacy of mTOR 
inhibitors is still uncertain. It is believe that with continued 
research of mTOR inhibitors, it can provide new strategies 
and methods for the clinical treatment of lung cancer[23-25].
  In summary, everolimus inhibits the growth of A549 cells, 
which is related with its cycle arrest and induction of 
apoptosis; mTOR signaling pathway plays an important role 
in tumor formation. On this basis, further study of the mTOR 
signaling pathway and its upstream and downstream genes 
to understand the pathogenesis of cancer. It can prove the 
pathogenesis and targeted therapy for lung cancer through 
further study of everolimus effect and action mechanism.
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